Novo Nordisk announced on 24 November 2025 the end of its phase 3 EVOKE and EVOKE+ trials, which investigated oral semaglutide – the active ingredient in Rybelsus, approved for type 2 diabetes – as a potential treatment... (Audio Available – 365 words – 2 minute read time)